883984-95-0 | Page 2 of 2 | Heterocyclic Building Blocks-piperidine

Burgey, Christopher S. et al. published their patent in 2006 |CAS: 883984-95-0

The Article related to oxoazepanyl oxospiropiperidinepyrrolopyridinecarboxamide preparation cgrp receptor antagonist, headache treatment oxohomopiperidinyl spiropiperidinepyrrolopyridinecarboxamide preparation and other aspects.Recommanded Product: Benzyl 7′-chloro-2′-oxo-1′,2′-dihydrospiro[piperidine-4,4′-pyrido[2,3-d][1,3]oxazine]-1-carboxylate

On April 20, 2006, Burgey, Christopher S.; Deng, James Z.; Potteiger, Craig; Williams, Theresa M. published a patent.Recommanded Product: Benzyl 7′-chloro-2′-oxo-1′,2′-dihydrospiro[piperidine-4,4′-pyrido[2,3-d][1,3]oxazine]-1-carboxylate The title of the patent was Preparation of oxohomopiperidinyl oxospiropiperidinepyrrolopyridinecarboxamides and related compounds as calcitonin gene-related peptide (CGRP) receptor antagonists.. And the patent contained the following:

Title compounds [I; A = bond, C(R2)2, O, SOm, NR2; B = [C(R2)2]n; R1, R2 = H, (substituted) alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl; pairs of R2 may form rings; R3 = H, F, cyano, (substituted) alkyl, CO2R4; R4 = H, (substituted) alkyl, fluoroalkyl, cycloalkyl, aryl, heteroaryl, PhCH2; X = C, S; Y = O, (R4)2, NCN, NHSO2Me, NCONH2; or Y = O2 when X = S; J = bond, C(R6)2, O, NR6; V = bond, C(R6)2, O, SOm, NR6, NR6NR6, etc.; Q = CR7a, C(R7A)2, CO, SOm, N, NR7a; T = CR7b, C(R7b)2, CO, SOm, N, NR7b; R6 = H, halo, OR4, CO2R4, alkyl, cycloalkyl, (substituted) aryl, heteroaryl, heterocyclyl, etc.; R7a, R7b = R2; R7aR7b = atoms to form cycloalkyl, aryl, heterocyclyl, heteroaryl rings; m = 0-2; n = 0, 1], were prepared for treatment of headache (no data). Thus, (3R,6S)-3-amino-6-(2,3-difluorophenyl)-1-(2,2,2-trifluoroethyl)azepan-2-one (preparation given) and 4-nitrophenyl chloroformate in THF at 0° were treated with Et3N; after 60 min. spiro[piperidine-4,3′-pyrrolo[2,3-b]pyridin]-2′(1’H)-one dihydrochloride (preparation given) and Et3N in CHCl3 were added followed by warming to room temperature to give title compound (II). The experimental process involved the reaction of Benzyl 7′-chloro-2′-oxo-1′,2′-dihydrospiro[piperidine-4,4′-pyrido[2,3-d][1,3]oxazine]-1-carboxylate(cas: 883984-95-0).Recommanded Product: Benzyl 7′-chloro-2′-oxo-1′,2′-dihydrospiro[piperidine-4,4′-pyrido[2,3-d][1,3]oxazine]-1-carboxylate

Referemce:
Piperidine – Wikipedia,
Piperidine | C5H11N – PubChem

Burgey, Christopher S. et al. published their patent in 2006 |CAS: 883984-95-0

The Article related to imidazoloazepane triazoloazepane preparation pharmaceutical composition cgrp receptor antagonist, triazoloazepane imidazoloazepane preparation treatment headache migraine cgrp receptor antagonist and other aspects.Quality Control of Benzyl 7′-chloro-2′-oxo-1′,2′-dihydrospiro[piperidine-4,4′-pyrido[2,3-d][1,3]oxazine]-1-carboxylate

On April 27, 2006, Burgey, Christopher S.; Paone, Daniel V.; Shaw, Anthony W.; Nguyen, Diem N.; Deng, Zhengwu J.; Williams, Theresa M.; Vacca, Joseph P.; Selnick, Harold G.; Potteiger, Craig M. published a patent.Quality Control of Benzyl 7′-chloro-2′-oxo-1′,2′-dihydrospiro[piperidine-4,4′-pyrido[2,3-d][1,3]oxazine]-1-carboxylate The title of the patent was Imidazolo[1,2-a]azepane and triazolo[4,3-a]azepane derivatives as CGRP receptor antagonists and their preparation, pharmaceutical compositions, and use for treatment of diseases in which CGRP is involved such as headache, migraine and cluster headache. And the patent contained the following:

Compounds of formula I and formula II are useful as antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as headache, migraine and cluster headache. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved. Compounds of formula I and II wherein Z is (un)substituted piperidine or (un)substituted spiropiperidine; A is C(R2)2, O, SOm, or NR2; B is [C(R2)2]n; D is N or CR1; R1 is H, (un)substituted C1-6 alkyl, (un)substituted C2-6 alkenyl, (un)substituted C2-6 alkynyl, (un)substituted C3-6 cycloalkyl, (un)substituted heterocyclyl, or (un)substituted (hetero)aryl; each R2 is independently H, (un)substituted C0-6 alkyl, (un)substituted C2-6 alkenyl, (un)substituted C2-6 alkynyl, (un)substituted C3-6 cycloalkyl, (un)substituted heterocyclyl, (un)substituted (hetero)aryl; any two R2 on the same or adjacent atoms optionally join to form cycloalkyl, (hetero)aryl, or heterocycloalkyl ring; W is O, NR4 or C(R4)2; R4 is H, (un)substituted (fluoro)C1-6 alkyl, (un)substituted C3-6 cycloalkyl, and (un)substituted (hetero)aryl, or benzyl; X is C or S; Y is O, (R4)2, NCN, NSO2Me or NCONH2; or Y is O2 when X is S; m is O, 1, or 2; n is 1 or 2; and pharmaceutically acceptable salts and diastereoisomers thereof are claimed in this invention. Example compound III was prepared by condensation of N-[(3R,6S)-6-(2,3-difluorophenyl)-2-thioxoazepan-3-yl]-4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxamide with 1-amino-3-methylbutan-2-ol to give N-[(3R,6S)-6-(2,3-difluorophenyl)-2-[(2-hydroxy-3-methylbutyl)imino]azepan-3-yl]-4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxamide TFA salt, which underwent oxidation to give example compound III. All the invention compounds were evaluated for their activity as antagonists of the CGRP receptor. From the assay, the example compounds, in general, exhibited Ki or IC50 values of less than about 50 μM. The experimental process involved the reaction of Benzyl 7′-chloro-2′-oxo-1′,2′-dihydrospiro[piperidine-4,4′-pyrido[2,3-d][1,3]oxazine]-1-carboxylate(cas: 883984-95-0).Quality Control of Benzyl 7′-chloro-2′-oxo-1′,2′-dihydrospiro[piperidine-4,4′-pyrido[2,3-d][1,3]oxazine]-1-carboxylate

Referemce:
Piperidine – Wikipedia,
Piperidine | C5H11N – PubChem

Paone, Daniel V. et al. published their patent in 2006 |CAS: 883984-95-0

The Article related to oxoimidazopyridylpiperidinylcarbonylaminopyridone preparation calcitonin gene related peptide antagonist, cgrp antagonist pyridone oxoimidazopyridyl piperidinyl carbamoyl preparation, piperidinecarboxamide oxopyridyl oxoimidazopyridyl preparation headache migraine treatment and other aspects.Name: Benzyl 7′-chloro-2′-oxo-1′,2′-dihydrospiro[piperidine-4,4′-pyrido[2,3-d][1,3]oxazine]-1-carboxylate

On September 21, 2006, Paone, Daniel V.; Nguyen, Diem N.; Shaw, Anthony W.; Burgey, Christopher S.; Tucker, Thomas J.; Graham, Samuel L. published a patent.Name: Benzyl 7′-chloro-2′-oxo-1′,2′-dihydrospiro[piperidine-4,4′-pyrido[2,3-d][1,3]oxazine]-1-carboxylate The title of the patent was Preparation of oxoimidazopyridylpiperidinylcarbonylaminopyridones and related compounds as calcitonin gene-related peptide (CGRP) receptor antagonists. And the patent contained the following:

Title compounds [I; Z = Q1, Q2; A = N, CR2; B = O, S; R1, R2, R7a, R7b = H, (substituted) alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl; R1R2, R2R2 = atoms to form rings; R3 = H, F, cyano, CO2R4, (substituted) alkyl; W = O, NR4, C(R4)2; X = C, S; Y = O, (R4)2, NCN, NCONH2, O2; J = bond, C(R6)2, O, NR6; V = bond, C(R6)2, O, S, SO, SO2, NR6, etc.; GL = N, NC(R6)2, C:CR6, CN, CR6, etc.; Q = CR7a, C(R7a)2, CO, S, SO, SO2, N, NR7a; T = CR7b, C(R7b)2, CO, S, SO, SO2, N, NR7b; with provisos], were prepared for treatment of headache, migraine, and cluster headache. Thus, N-(5-bromo-1-methyl-2-oxo-1,2-dihydropyridin-3-yl)-4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxamide (preparation given), phenylboronic acid, diisopropylamine, Pd(OAc)2, and 3,3′,3”-phosphinidynetris(benzenesulfonic acid) trisodium salt were heated in DMF/H2O at 80° for 18 h to give N-(1-methyl-2-oxo-5-phenyl-1,2-dihydropyridin-3-yl)-4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxamide as the trifluoroacetate. I generally antagonized CGRP receptors with Ki or IC50 values of ≤50 μM. The experimental process involved the reaction of Benzyl 7′-chloro-2′-oxo-1′,2′-dihydrospiro[piperidine-4,4′-pyrido[2,3-d][1,3]oxazine]-1-carboxylate(cas: 883984-95-0).Name: Benzyl 7′-chloro-2′-oxo-1′,2′-dihydrospiro[piperidine-4,4′-pyrido[2,3-d][1,3]oxazine]-1-carboxylate

Referemce:
Piperidine – Wikipedia,
Piperidine | C5H11N – PubChem

A new application about 883984-95-0

One of the oldest and most widely used commercial enzyme inhibitors is aspirin, Formula: C19H18ClN3O4, which selectively inhibits one of the enzymes involved in the synthesis of molecules that trigger inflammation. you can also check out more blogs about 883984-95-0

Catalysts function by providing an alternate reaction mechanism that has a lower activation energy than would be found in the absence of the catalyst. In some cases, the catalyzed mechanism may include additional steps.In a article, 883984-95-0, molcular formula is C19H18ClN3O4, introducing its new discovery. Formula: C19H18ClN3O4

Compounds of Formula (I): and Formula (II): (where variables R2 , R4, A, B, D, W, X, Y and Z are as defined herein) useful as antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as headache, migraine and cluster headache. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

Reference：
Piperidine – Wikipedia,
Piperidine | C5H23909N – PubChem

Awesome and Easy Science Experiments about 883984-95-0

I hope this article can help some friends in scientific research. I am very proud of our efforts over the past few months and hope to 883984-95-0, help many people in the next few years.HPLC of Formula: C19H18ClN3O4

A catalyst don’t appear in the overall stoichiometry of the reaction it catalyzes, HPLC of Formula: C19H18ClN3O4, but it must appear in at least one of the elementary reactions in the mechanism for the catalyzed reaction. 883984-95-0, Name is Benzyl 7′-chloro-2′-oxo-1′,2′-dihydrospiro[piperidine-4,4′-pyrido[2,3-d][1,3]oxazine]-1-carboxylate, molecular formula is C19H18ClN3O4. In a Patent, authors is ，once mentioned of 883984-95-0

The present invention relates to new CGRP-antagonists of general formulae Ia and Ib wherein R1, R2, R3, R4 and R5 are defined as mentioned below, the tautomers, the isomers, the diastereomers, the enantiomers, the hydrates, the mixtures and the salts thereof as well as the hydrates of the salts, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases, pharmaceutical compositions containing these compounds, the use thereof and processes for the preparation thereof.

Reference：
Piperidine – Wikipedia,
Piperidine | C5H23903N – PubChem

New learning discoveries about 883984-95-0

883984-95-0 Benzyl 7′-chloro-2′-oxo-1′,2′-dihydrospiro[piperidine-4,4′-pyrido[2,3-d][1,3]oxazine]-1-carboxylate 59165781, apiperidines compound, is more and more widely used in various fields.

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.883984-95-0,Benzyl 7′-chloro-2′-oxo-1′,2′-dihydrospiro[piperidine-4,4′-pyrido[2,3-d][1,3]oxazine]-1-carboxylate,as a common compound, the synthetic route is as follows.

INTERMEDIATE 16 r-(Methoxymethvnspirorpiperidine-4.4′-pyrido[2.3-(iiri.31oxazinl-2riy)-one Step A. Benzyl 7′-chloro-l’-(‘methoxymethyl)-2′-oxo-r,2′-dihvdro-lH-spiro[piperidme-4,4’- pyridor2.3-lithium bis(trimethylsilyl)amide (2.86 niL of IM solution, 2.86 mmol) followed by chloromethyl methyl ether (0.094 mL, 1.01 mmol). After 0.5 h, the reaction was diluted with EtOAc, extracted with water (3x) and brine, dried over MgSO4, filtered, and concentrated under reduced pressure. The crude product was purified by silica gel chromatography, eluting with a gradient of 0 to 20% ethyl acetate : dichloromethane to give the title compound (0.21 g). MS 432.1 (M + 1)., 883984-95-0

Reference£º
Patent; MERCK & CO., INC.; WO2006/44504; (2006); A1;,
Piperidine – Wikipedia
Piperidine | C5H11N – PubChem

Simple exploration of 883984-95-0

883984-95-0, The synthetic route of 883984-95-0 has been constantly updated, and we look forward to future research findings.

883984-95-0, Benzyl 7′-chloro-2′-oxo-1′,2′-dihydrospiro[piperidine-4,4′-pyrido[2,3-d][1,3]oxazine]-1-carboxylate is a piperidines compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

INTERMEDIATE 13 r-Methylspiro[piperidine-4,4′-pyridor2.3-6?[l,31oxazinl-2Yrff)-oneStep A. Benzyl 7′-chloro-r-methyl-2′-oxo-r.2′-dihydro-lH-spiro[piperidine-4,4′-pyrido[2,3- d [1 ,3″|oxazine]-l -carboxylate; To a 0 C solution of benzyl 7′-chloro-2′-oxo-ll,2′-dihydro-lH-spiro[piperidine- 4,4′-pyrido[2,3-<^[l,3]oxazine]-l-carboxylate (0.56 g, 1.43 mmol) in DMF (14 niL) was added lithium bis(trimethylsilyl)amide (2.86 mL of IM solution, 2.86 mmol) followed by methyl iodide (0.11 mL, 2.28 mmol). After Ih, more methyl iodide was added (0.55 mL, 1.14 mmol). After a further Ih, the reaction was diluted with EtOAc, extracted with water (3x) and brine, dried over MgSO4, filtered, and concentrated under reduced pressure. The crude product was purified by silica gel chromatography, eluting with a gradient of 0 to 4% methanol : dichloromethane to give the title compound (0.47 g). MS 402.0 (M + 1). 883984-95-0, The synthetic route of 883984-95-0 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; MERCK & CO., INC.; WO2006/44504; (2006); A1;,
Piperidine – Wikipedia
Piperidine | C5H11N – PubChem

Brief introduction of 883984-95-0

The synthetic route of 883984-95-0 has been constantly updated, and we look forward to future research findings.

883984-95-0, Step 3: spiro[piperidine-4,4′-pyrido[2,3-d][1,3]oxazin]-2′(1’H)-one hydrochloride 16.40 g (0.04 mol) benzyl 7′-chloro-2′-oxo-1′,2′-dihydrospiro[piperidine-4,4′-pyrido[2,3d]-[1,3]oxazine]-1-carboxylate and 2.00 g palladium(Pd/C 10%) in 500 mL EtOH were hydrogenated for 6 h at RT in a hydrogen atmosphere. Then 1 g of palladium (Pd/C 10%) were additionally added and the mixture was hydrogenated for a further 3 h at RT in a hydrogen atmosphere. After filtration of the reaction mixture the solvent was eliminated in vacuo. The residue was triturated with EtOH, the precipitate formed was suction filtered, washed with EtOH and dried in the drying cupboard for 3 h at 50 C.Yield: 5.40 g (50% of theoretical)ESI-MS: m/z=220 (M+H)+ Rt(HPLC): 0.90 min (method C)

The synthetic route of 883984-95-0 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; BOEHRINGER INGELHEIM INTERNATIONAL GMBH; US2012/149698; (2012); A1;,
Piperidine – Wikipedia
Piperidine | C5H11N – PubChem